Related Experiment Video

Updated: Oct 29, 2025

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.5K

Prognostic impact of chromogranin A in patients with acute heart failure

Hong Nyun Kim1,2, Dong Heon Yang1,2,3, Bo Eun Park1

  • 1Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea.

Yeungnam University Journal of Medicine
|July 8, 2021
PubMed

Insights

Chromogranin A (CgA) shows prognostic value comparable to NT-proBNP in acute heart failure patients. Combining CgA and NT-proBNP improves the prediction of adverse outcomes.

Area of Science:

  • Cardiology
  • Biomarker Research
  • Clinical Prognostics

Background:

  • Chromogranin A (CgA) is a potential mortality predictor in heart failure.
  • Limited data exists on CgA's prognostic value and clinical utility.
  • This study compares CgA to established natriuretic peptide biomarkers in acute heart failure.

Purpose of the Study:

  • To evaluate the prognostic capability of CgA in acute heart failure.
  • To compare CgA's predictive power against N-terminal pro-B-type natriuretic peptide (NT-proBNP).
  • To assess the combined prognostic value of CgA and NT-proBNP.

Main Methods:

  • Retrospective analysis of 272 acute heart failure patients.
  • CgA levels measured during hospitalization (June 2017-June 2018).
  • 1-year composite endpoint of death and heart failure hospitalization.

Main Results:

  • CgA demonstrated prognostic value comparable to NT-proBNP (AUC 0.697 vs. 0.737).
  • High CgA levels correlated with significantly worse 1-year outcomes (p<0.001).
  • Combining CgA and NT-proBNP improved adverse event prediction.

Conclusions:

  • CgA is a valuable prognostic biomarker in acute heart failure, similar to NT-proBNP.
  • The combined use of CgA and NT-proBNP enhances prognostic accuracy.
  • CgA offers incremental value when added to existing risk factors and NT-proBNP.
Abstract

Keywords:
BiomarkersChromogranin AHeart failurePrognosis

More Related Videos

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

328
Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis04:05

Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis

Published on: June 30, 2023

2.4K

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
122
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
612
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
55
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
104
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
867
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
85